镭-223联合恩扎卢胺治疗骨转移去势抵抗性前列腺癌的骨折风险与既往阿比特龙暴露:真实世界研究
既往阿比特龙暴露未增加骨折风险(OR 1.00;95%CI 0.37-2.71),而骨健康药物使骨折可能性降低79%(OR 0.21;95%CI 0.07-0.57;p=0.010)。
要点
- 镭-223联合恩扎卢胺治疗者中15%发生骨折。
- 既往阿比特龙暴露与骨折风险无显著关联(OR 1.00)。
- 骨健康药物与骨折风险降低79%相关(OR 0.21;p=0.010)。
核心结论
- 在镭-223联合恩扎卢胺治疗的转移性去势抵抗性前列腺癌患者中,既往阿比特龙暴露与骨折无关联,骨健康药物可降低骨折发生率。
主要发现
- 171例患者中15%发生骨折。
- 既往阿比特龙未增加骨折风险(OR 1.00;95%CI 0.37-2.71)。
- 骨健康药物使骨折可能性降低79%(OR 0.21;95%CI 0.07-0.57;p=0.010)。
关键数值与推荐
- 骨折发生率15%;既往阿比特龙OR 1.00(95%CI 0.37-2.71);骨健康药物OR 0.21(95%CI 0.07-0.57;p=0.010)。
临床怎么用
- 对接受镭-223联合恩扎卢胺的骨转移去势抵抗性前列腺癌患者,应重视骨健康管理,考虑使用骨健康药物以降低骨折风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: To assess fracture risk in men with metastatic castration-resistant prostate cancer treated with radium-223 (Ra-223) plus enzalutamide and with prior abiraterone exposure. SUBJECTS/METHODS: We evaluated patients in the Komodo Health Research Dataset who started Ra-223 plus enzalutamide between January 2016 and December 2022. RESULTS: In total, 171 patients were identified; 15% developed fractures. Prior abiraterone did not increase fracture risk (OR 1.00; 95% CI 0.37-2.71), and bone health agents (BHAs) lowered fracture likelihood by 79% (OR 0.21; 95% CI 0.07-0.57; p = 0.010). CONCLUSIONS: In Ra-223 plus enzalutamide recipients, prior abiraterone was not associated with fractures and BHAs reduced fracture incidence.
引用
- McKay RR, Lunacsek O, Korn MJ, et al. Bone fractures and prior abiraterone use in men treated with radium-223 plus enzalutamide for castration-resistant prostate cancer with bone metastases: a real-world study. Prostate Cancer Prostatic Dis. 2026. PMID: 42966775. doi:10.1038/s41391-026-01170-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。